Nuwellis Inc. (NASDAQ:NUWE) shares plunged 65.2% in premarket trading on Friday after the medical technology company announced a heavily discounted public offering designed to raise approximately $6 million.
The financing was priced at $0.30 per share, significantly below recent market levels, triggering a sharp selloff as investors assessed the potential impact of dilution.
Company Issues 20 Million Shares and Warrants
Under the terms of the transaction, Nuwellis will issue 20 million shares of common stock together with Series C and Series D warrants.
The offering is expected to generate gross proceeds of approximately $6 million before deducting placement agent fees and other related expenses.
Management has not disclosed a detailed allocation of proceeds but is expected to use the funds to support ongoing corporate and operational requirements.
Warrants Carry Five-Year Exercise Period
Both the Series C and Series D warrants have an exercise price of $0.30 per share.
The warrants will become exercisable for a five-year period following shareholder approval and the completion of a reverse stock split, as required under Nasdaq regulations.
The structure gives investors the opportunity to purchase additional shares in the future at the same price as the current offering.
Series C and Series D Warrants Include Special Features
The financing package includes Series C warrants covering up to 60 million common shares and Series D warrants covering up to 20 million shares.
Series C warrants contain a one-time adjustment mechanism linked to any future reverse stock split implemented by the company.
Meanwhile, the Series D warrants include a zero-cash exercise feature, allowing holders to receive shares without making an additional cash payment under specified conditions.
Existing Warrants Repriced Through Separate Agreement
Alongside the public offering, Nuwellis entered into private agreements with certain holders of previously issued warrants.
Under those arrangements, the exercise price of existing warrants will be reduced to $0.30 per share, aligning them with the pricing of the new offering.
The repricing transactions remain subject to shareholder approval before they can take effect.
Financing Led by Ladenburg Thalmann
Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the offering.
The transaction represents a significant capital-raising effort for the company as it seeks to strengthen its financial position and support future operations.
Focus Remains on Cardiorenal Medical Technologies
Nuwellis develops medical technologies designed for patients suffering from cardiorenal conditions, a category that includes interconnected heart and kidney disorders.
The company continues to focus on expanding the adoption of its therapeutic solutions while pursuing initiatives aimed at supporting long-term growth.
However, the size of the offering, its discounted pricing and the large number of attached warrants raised concerns among investors, contributing to the sharp decline in the stock following the announcement.